| http://www.w3.org/ns/prov#value | - Or, perhaps there is an explanation somewhere within the FDA's Follow-Up to the November 2009 Early Communication about an Ongoing Safety Review of Sibutramine, Marketed as Meridia, issued on January 21, 2010.Lastly, for those who want to dig deeper, you can read about the recent Meridia study, itself -- A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiova
|
